• 921 Citations
  • 17 Scopus h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Sikander Ailawadhi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 21 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Waldenstrom Macroglobulinemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Dexamethasone Medicine & Life Sciences
Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidemiology Medicine & Life Sciences
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma

Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M. H., Posner, G., Ralston, S., Zagadailov, E., Ba-Mancini, A. & Rifkin, R., Jan 1 2019, In : Clinical therapeutics.

Research output: Contribution to journalArticle

Multiple Myeloma
Costs and Cost Analysis
Subcutaneous Infusions
3 Citations (Scopus)

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan Khan, A. A., Ruehle, M., Rharbaoui, F., Haeder, T., Wartenberg-Demand, A. & Anderson, K. C., Jan 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia.

Research output: Contribution to journalArticle

Multiple Myeloma
Appointments and Schedules

Influence of Sociodemographic Factors on Treatment Decisions in Non–Small-Cell Lung Cancer

Duma, N., Idossa, D. W., Durani, U., Frank, R. D., Paludo, J., Westin, G., Lou, Y., Mansfield, A. S., Adjei, A. A., Go, R. S. & Ailawadhi, S., Jan 1 2019, (Accepted/In press) In : Clinical Lung Cancer.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Treatment Refusal
Drug Therapy

Monoclonal antibody utilization characteristics in patients with multiple myeloma

Ailawadhi, S., Sher, T., Azzouqa, A. G., Meghji, Z., Jain, T., Jani, P., Ahmed, S., Diehl, N., Roy, V., Shah, V., Hodge, D., Ailawadhi, M., Alegria, V. R., Paulus, A., Chanan Khan, A. A. & Fonseca, R., Sep 1 2019, In : Anti-cancer drugs. 30, 8, p. 859-865 7 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Monoclonal Antibodies
Clinical Trials
Drug Utilization
1 Citation (Scopus)

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 others, Berdeja, J. G., Feb 1 2019, In : Blood cancer journal. 9, 2, 17.

Research output: Contribution to journalArticle

Open Access
Multiple Myeloma
Anti-Idiotypic Antibodies
Maximum Tolerated Dose
Pharmaceutical Preparations